Market Place
Sourcing Support
Novartis`s Fabhalta Receives Approval in Canada
06 Jan 2025 //
HEALTH CANADA
Novartis`s Biologic Ilaris Receives Suppl Approval in US
01 Nov 2024 //
FDA
Novartis`s Biologic Cosentyx (Secukinumab) Receives Approval in US
04 Oct 2024 //
FDA
Novartis Pharms Corp Biologic Crizanlizumab-Tmca Receives Approval in US
26 Jun 2024 //
FDA
Novartis` Arzerra (ofatumumab) Receives Suppl Approval in the U.S.
12 Apr 2024 //
FDA
Novartis` Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.
12 Apr 2024 //
FDA
Novartis` Biologic Cosentyx (secukinumab) Receives Approval in the U.S.
31 Oct 2023 //
FDA
Novartis` Tevimbra (tislelizumab) Receives Approval in Europe
10 Oct 2023 //
EMA
Novartis` Locametz (Gozetotide) Receives Approval in Europe
29 Jun 2023 //
EMA
Novartis`s Cosentyx (secukinumab) Receives Approval in Europe
13 Jun 2023 //
EMA
Novartis` Prometax (rivastigmine) Receives Approval in Europe
08 Jun 2023 //
EMA
Novartis` Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.
11 May 2023 //
FDA
Novartis` Generic Tafinlar (Dabrafenib) Receives Approval in the U.S.
16 Mar 2023 //
FDA
Novartis Europharm`s Locametz (gozetotide) Receives Approval in Europe
02 Feb 2023 //
EMA
Novartis` Biologic Beovu ( Brolucizumab) Receives Approval in the U.S.
19 Dec 2022 //
FDA
Novartis` Kesimpta Receives Approval in Europe
08 Dec 2022 //
EMA
Novartis` Atectura Breezhaler Receives Approval in Europe
08 Dec 2022 //
EMA
Novartis` Biologic Adakveo (Crizanlizumab) Receives Approval in the U.S.
08 Sep 2022 //
FDA
Novartis`s Scemblix (asciminib) Receives Approval in Europe
07 Sep 2022 //
EMA
Novaris`s Biologic Arzerra (Ofatumumab) Receives Approval in the U.S.
02 Sep 2022 //
FDA
Novartis Pharms` Biologic Beovu (Brolucizumab) Receives Approval in the U.S.
18 Feb 2022 //
FDA
Novartis` Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.
22 Dec 2021 //
FDA
Novartis`s Extavia (Interferon Beta-1b Receives Supplemental Approvals in US
04 Nov 2021 //
FDA
Novartis Pharms`s Biological Interferon Beta-1B Receives Approval In US
02 Oct 2020 //
FDA
Novartis Pharms`s Biological Canakinumab Receives Approval In US
22 Sep 2020 //
FDA
Novartis`s Arzerra (Ofatumumab) Receives Supplemental Approval in US
22 Aug 2020 //
FDA
Novartis`s Kesimpta (Ofatumumab) Receives Supplemental Approval in US
22 Aug 2020 //
FDA
Novartis Europharm `s Piqray (alpelisib) Receives Approval in Europe
31 Jul 2020 //
EMA
Novartis Euro`s Enerzair Breezhaler(indacaterol) Receives Approval in Europe
22 Jul 2020 //
EMA
Novartis Europharm Generic Bemrist (Indacaterol)Receives Approval in Europe
24 Jun 2020 //
EMA
Novartis`s Cosentyx (Secukinumab) Receives Supplemental Approval in US
23 Jun 2020 //
FDA
Novartis`s Beovu (brolucizumab-dbll) Receives Supplemental Approval in US
16 Jun 2020 //
FDA
AveXis EU Zolgensma (onasemnogene abeparvovec) Receives Approval in Europe
27 May 2020 //
EMA
Novartis Europharm Mayzent (siponimod) Recieves Approval in Europe
13 Jan 2020 //
EMA
Novartis`s Adakveo (Crizanlizumab) Receives Supplemental Approval in US
18 Nov 2019 //
FDA
Novartis Beovu (Brolucizumab-dbII) Receives Approval In US
08 Oct 2019 //
FDA
Novartis` Biological Interferon Beta-1B Receives Supplemental Approval in US
12 Dec 2018 //
FDA
Novartis` Cosentyx (secukinumab) Receives Approval for Europe
26 Oct 2018 //
EMA
Novartis` Biological Kymriah Receives Approval in Europe
24 Sep 2018 //
EMA
Novartis` Kymriah (tisagenlecleucel) Receives Approval in Europe
20 Sep 2018 //
EMA
Novartis` Aimovig(erenumab) Receives Approval in Europe
10 Aug 2018 //
EMA
Novartis Europharm Ltd Rydapt (midostaurin) Recieves Approval in Europe
26 Oct 2017 //
EMA
Novartis Pharm’s Cosentyx (Secukinumab) Receives Supplemental Approval In US
18 Sep 2017 //
FDA
Novartis Europharm`s Imraldi (adalimumab) Receives Approval in Europe
01 Sep 2017 //
EMA
Novartis` Kisqali (Ribociclib) Receives Approval In US
13 Mar 2017 //
FDA
Novartis`s Supplement Ilaris (Canakinumab) Receives Approval In US
22 Dec 2016 //
FDA
FDA OK`s Novartis Biosimilar To Amgen Arthritis Drug, Enbrel
31 Aug 2016 //
FDA
Novartis` Farydak (panobinostat) approved for Cancer in Europe
11 Sep 2015 //
EMA
Novartis snags EU approval for multiple myeloma med Farydak
04 Sep 2015 //
FIERCE PHARMA
Novartis`s Odomzo (Sonodegib) approved for carcinoma in Europe
04 Sep 2015 //
EMA
FDA approves new treatment for most common form of advanced skin cancer
25 Jul 2015 //
FDA
Novartis` Entresto (sacubitril/valsartan) Approved in US For Heart Failure
09 Jul 2015 //
FDA
Novartis` Zykadia (Ceritinib) Approved in Europe For Lung Cancer
05 Jun 2015 //
EMA
Novartis` Gilenya (Fingolimod) Receives Supplemental Approval in US For MS
16 May 2015 //
FDA
Novartis’ Zykadia (Ceritinib) Approved In Europe For ALK and NSCLC
09 May 2015 //
NOVARTIS
